Integra LifeSciences(NASDAQ) IART

Integra LifeSciences Holdings Corporation makes tools for surgeons to repair bodies. These products help doctors treat brain injuries and skin wounds. They help patients recover from complex health conditions.

Tools for the Operating Room

• Specialty Surgery: Equipment and monitors used for brain surgery and general operations; represents approximately 70% of revenue.
• Tissue Reconstruction: Materials that help the body regrow skin and repair damaged nerves; accounts for about 30% of revenue.
• Neurosurgery: Specialized technology used to manage brain tumors and traumatic head injuries.
• Surgical Instruments: A catalog of reusable and disposable tools for hospitals and clinics.
• ENT Solutions: Technology for ear, nose, and throat procedures like sinus and airway dilation.

Strategic Shifts and New Sites

• Opened the Braintree manufacturing facility in June 2026 to support product relaunches.
• Acquired rights for Durepair Dural Regeneration Matrix in 2024 and launched it in October 2025.
• Started a restructuring plan in the fourth quarter of 2025 to improve supply stability.
• Gained clearance from the Food and Drug Administration (FDA) for a cardiac tool in Nov. 2025.

What Sets the Company Apart

The company manages research and production sites in the United States, Europe, and Asia. It specializes in bioengineering collagen and developing electronic tools to solve complex surgical problems.

Recent Financial Performance

• Total revenue was $418.8 million in the three months ended June 30, 2026.
• Gross margin reached 52.5% of revenue for the three-month period ended June 30, 2026.
• Net income was $4.5 million for the three months ended June 30, 2026.
• Working capital rose to $860.6 million as of June 30, 2026.

Bottom Line

Integra LifeSciences has transitioned from a tissue engineering firm into a global medical technology provider. The company integrates regenerative materials with surgical tools to support a wide range of patient needs.